ABS1046 EFFECTS OF VAGUS NERVE STIMULATION IN QUALITY OF LIFE AND PAIN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, A RANDOMIZED PLACEBO-CONTOLLED CLINICAL TRIAL

医学 安慰剂 迷走神经电刺激 生活质量(医疗保健) 迷走神经 随机对照试验 刺激 临床试验 麻醉 物理疗法 内科学 替代医学 病理 护理部
作者
Amanda Hempel Zinglersen,Mogens Pfeiffer‐Jensen,Christina Brock,Søren Jacobsen
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:84: 2252-2252
标识
DOI:10.1016/j.ard.2025.06.1915
摘要

Background: SLE is an autoimmune disease of unknown origin. Pain and reduced health-related quality of life (HRQoL) are major challenges within systemic lupus erythematosus (SLE) and remain inadequately addressed by conventional immunosuppressive therapies. Transcutaneous vagus nerve stimulation (tVNS) has shown potential to modulate systemic inflammation via the cholinergic anti-inflammatory reflex and our preliminary results have indicated effects on symptoms such as fatigue (Zinglersen et al. 2024). Objectives: To investigate if tVNS as adjuvant treatment to standard care could improve patient-reported levels of HRQoL and pain in SLE patients. Methods: SLE patients with signs of fatigue (FACIT-F score <40) and autonomic dysfunction (Composite Autonomic Symptoms Score >12) were randomized 1:1 to active or placebo tVNS in this double-blinded parallel-group study (Zinglersen et al. 2022). In work package (WP)1 (one week), the patients performed four minutes of tVNS four times daily. After a 2-week pause, WP2 (eight weeks) entailed four minutes of tVNS, but only two times daily. The patients completed the questionnaires before and after each WP, and one week into WP2. The patients completed the Short Form-12 (SF-12) questionnaire, which includes nine items addressing various aspects of health-related quality of life (HRQoL). From their responses, two component scores were derived: one reflecting physical- (PCS) and the other reflecting mental- HRQoL (PCS). Additional average joint and muscle pain levels were assessed using a Visual Analog Scale (VAS), rating the average pain intensity experienced over the past week on a scale from 0 (no pain) to 10 (worst possible pain). Linear mixed modeling of repeated measures was performed to examine effects of tVNS in WP1 and WP2, respectively. Results: Sixty-one patients were included in the analyses (30 placebo, 31 active tVNS). All the patients' mean age was 47.6 years (±14.2 SD), and 91.8% were women. There were no differences in baseline levels of age, sex, PCS, MCS or VAS pain (data not shown, all p>0.05). Figure 1 illustrates PCS, MCS and pain during the study, separated into WP1 and WP2. PCS improved more in the active-treatment group than in the placebo-group during the study: During WP1 the active treatment-group increased their PCS with 7.3% more than the placebo group, however not statistically significant (p=0.09). In WP1 week 1 there was a similar pattern with an 8.7% relative increase in the active treatment group, p=0.07. Interestingly, during the full eight weeks of WP2, the active treatment group improved their PCS by 11.3% compared to the placebo group, which was statistically significant (p=0.03). However, neither MCS nor pain changed during the study (p>0.05). Conclusion: Vagus nerve stimulation (VNS) shows potential as a novel therapeutic strategy for enhancing the physical components of HRQoL in SLE. Short-term stimulation protocols (two vs. four sessions per day over one week) showed no significant differences, while long-term treatment over eight weeks significantly improved PCS. However, VNS did not improve self-reported pain or mental HRQoL. These findings highlight the need for larger, randomized controlled trials to confirm efficacy and investigate underlying mechanisms. REFERENCES: [1] Zinglersen et al. AB1036 Annals of the Rheumatic Diseases 2024;83:1839. doi: 10.1136/annrheumdis-2024-eular.1975. [2] Zinglersen et al. BMJ Open. 2022 sep. 20;12(9):e064552. doi: 10.1136/bmjopen-2022-064552. Figure 1 Acknowledgements: NIL . Disclosure of Interests: None declared . © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
鹿呦发布了新的文献求助10
1秒前
1秒前
3113129605完成签到 ,获得积分10
1秒前
跳跃的曼凡完成签到,获得积分10
2秒前
咸鱼完成签到,获得积分10
3秒前
3秒前
脑洞疼应助qzaima采纳,获得10
3秒前
悟格完成签到,获得积分10
3秒前
star完成签到,获得积分10
4秒前
sky发布了新的文献求助10
4秒前
5秒前
忧心的碧发布了新的文献求助10
5秒前
6秒前
江郁清完成签到 ,获得积分10
6秒前
linglingling完成签到 ,获得积分10
7秒前
8秒前
9秒前
科研通AI6.3应助风中画板采纳,获得10
10秒前
等待书桃发布了新的文献求助10
10秒前
caiyuqing发布了新的文献求助10
11秒前
CipherSage应助阿尔喷斯少年采纳,获得10
11秒前
hyx9504完成签到,获得积分10
12秒前
悟格发布了新的文献求助10
13秒前
YY完成签到 ,获得积分10
13秒前
领导范儿应助忧心的碧采纳,获得10
13秒前
13秒前
傣妹纸如裴洱完成签到,获得积分10
14秒前
111发布了新的文献求助10
15秒前
15秒前
yl完成签到 ,获得积分10
15秒前
yjh123应助顺心的觅荷采纳,获得40
16秒前
思源应助咸鱼采纳,获得20
16秒前
呆萌的尔云完成签到 ,获得积分10
17秒前
CPUPPer完成签到,获得积分10
17秒前
死神完成签到,获得积分10
18秒前
18秒前
19秒前
李想完成签到,获得积分10
19秒前
脑洞疼应助李麟采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
APA handbook of comparative psychology: Basic concepts, methods, neural substrate, and behavior 1000
全员动态考核,锚定高质量发展:读懂同济大学教师人事改革新政的深层价值 900
Health Psychology 800
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
The fast track to determining transfer functions of linear circuits: The student guide 500
Römisch-Germanische Forschungen 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7594480
求助须知:如何正确求助?哪些是违规求助? 9171474
关于积分的说明 19631806
捐赠科研通 7172018
什么是DOI,文献DOI怎么找? 3267710
关于科研通互助平台的介绍 2432498
邀请新用户注册赠送积分活动 2260587